An RCT in postmenopausal individuals with ER+/unknown primary breast cancer found no difference in endocrine symptoms over 5 years of treatment in individuals who switched from tamoxifen to exemestane versus continuing on tamoxifen [35]. Here, ESR1 is linked to breast carcinoma.